Taysha Gene Therapies Inc. Common Stock (TSHA)
Stock · NASDAQ · Health Care
$3.63as of 10/16/2026
Price chart
Active signals
TSHA Signal Track Record
How signals performed across all stocks →What TSHA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.5% | 50% | September 14, 2026 |
| Bollinger Band Breakout | 21 | -7.5% | 38% | June 17, 2026 |
| Bollinger Band Breakdown | 20 | +0.3% | 55% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -4.9% | 25% | September 8, 2026 |
| Any 20-session window (baseline) | -2.6% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 99
- Website
- tayshagtx.com/
Fundamentals
- 1-day range
- $3.6$3.74
- Market cap
- $1.82B
- P/E (trailing)
- —
- P/E (forward)
- -7.83
- EPS (trailing)
- $-0.41
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 3.32M
How Taysha Gene Therapies Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Taysha Gene Therapies Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.46▼ 16.71%Market cap $1.69BP/E —$2.77$7.18
- IMCRImmunocore Holdings plc American Depositary Shares$29.4▼ 0.27%Market cap $1.66BP/E —$27.5$40.71
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- MAZEMaze Therapeutics Inc. Common Stock$27.53▲ 0.18%Market cap $1.58BP/E —$21.95$53.65
- SLBTSL Science Holding Limited Ordinary Shares$1.53▼ 1.29%Market cap $1.53BP/E —$1.42$14.5
- VIRVir Biotechnology Inc. Common Stock$9.96▼ 4.87%Market cap $1.48BP/E —$4.82$12
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.46 | ▼ 16.71% | $2.77$7.18 |
| IMCR Immunocore Holdings plc American Depositary Shares | $1.66B | — | $29.4 | ▼ 0.27% | $27.5$40.71 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| MAZE Maze Therapeutics Inc. Common Stock | $1.58B | — | $27.53 | ▲ 0.18% | $21.95$53.65 |
| SLBT SL Science Holding Limited Ordinary Shares | $1.53B | — | $1.53 | ▼ 1.29% | $1.42$14.5 |
| VIR Vir Biotechnology Inc. Common Stock | $1.48B | — | $9.96 | ▼ 4.87% | $4.82$12 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book ValueYahoo · 10/9/2026
- Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?Yahoo · 10/9/2026
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meetingbenzinga · 10/1/2026
- Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual MeetingYahoo · 10/1/2026
- Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual MeetingBenzinga · 10/1/2026
- Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform RatingBenzinga · 9/17/2026
- Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest ApprovalSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Nagendran Sukumar · July 10, 2026 · Sale200.0K @ $6.24
- Long Alison S · June 1, 2026 · Grant42.7K
- Long Alison S · June 1, 2026 · Grant21.3K
- Sepp-Lorenzino Laura · June 1, 2026 · Grant42.7K
- Sepp-Lorenzino Laura · June 1, 2026 · Grant21.3K
- John A. Stalfort III · June 1, 2026 · Grant42.7K
- John A. Stalfort III · June 1, 2026 · Grant21.3K
- Donenberg Phillip B. · June 1, 2026 · Grant42.7K
- Donenberg Phillip B. · June 1, 2026 · Grant21.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 261.44M
- Total value held
- $1.18B
- Institutional holders
- 187
- Unknown23.56M
- Unknown22.37M
- Unknown21.70M
- Unknown18.37M
- Unknown18.00M
- Unknown17.97M
- Unknown14.32M
- Unknown13.68M
- Unknown11.21M
- Unknown10.23M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views
Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.